Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience

  • SMART study to extend data beyond patient population studied in clinical trials
  • New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world experience and regulatory approvals in Europe and Canada



Basel, April 23, 2021 - Novartis today announced plans to initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) weighing

This site uses cookies and analysis tools to improve the usability of the site. More information. |